Clinical Trials Using Anti-HER2 ADC DS-8201a

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-HER2 ADC DS-8201a. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • DS8201a and Pembrolizumab in Participants With Locally Advanced / Metastatic Breast or Non-Small Cell Lung Cancer

    This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
    Location: 3 locations

  • Testing the Biological Effects of DS-8201a on Patients with Advanced Cancer

    This phase I trial studies the biological effects of DS-8201a on patients with HER2 positive cancer that has spread to other places in the body (advanced). DS-8201a works by binding to a protein called HER2 that is present on the surface of tumor cells. This allows DS-8201a to kill the tumor cells by damaging their deoxyribonucleic acid (DNA), resulting in tumor cell death. This study looks at how DS-8201a may affect the levels of certain proteins and immune cells in tumors and how well the drug works against tumor cells by examining cells from a small piece tumor taken before and after DS-8201a is given.
    Location: 2 locations

  • A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

    This study is designed to determine the efficacy and safety of durvalumab in combination with paclitaxel and durvalumab in combination with novel oncology therapies with or without paclitaxel for first-line metastatic triple negative breast cancer.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri